)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Vivoryon Therapeutics (VVY) investor relations material
Vivoryon Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary4 Sep, 2025
Executive summary
Focused on advancing varoglutamstat as a novel oral therapy for chronic and diabetic kidney disease, with strong clinical and preclinical evidence supporting efficacy and safety, and addressing significant unmet medical needs.
Achieved significant milestones in H1 2025, including positive Phase 2 data, new U.S. composition of matter patent for varoglutamstat (exclusivity through 2044, potential extension to 2049), and preparations for a Phase 2b DKD study.
Presented new preclinical and mechanistic data supporting efficacy in diabetic kidney disease and rare diseases like Fabry disease, with promising results in animal models and additive effects with SGLT-2 inhibitors.
Actively pursuing additional financing and partnerships to support late-stage clinical development and fund upcoming clinical trials.
Nomination of VY2149 as a next-generation QPCT/L inhibitor for future development.
Financial highlights
No revenue reported for H1 2025 or H1 2024.
R&D expenses for H1 2025 were €2.8M, down from €10.3M in H1 2024, mainly due to reduced clinical development and production costs.
G&A expenses decreased to €2.8M from €3.5M year-over-year, attributed to lower personnel and consulting costs.
Net loss narrowed to €5.5M in H1 2025 from €13.6M in H1 2024.
Cash and equivalents stood at €4.8M as of June 30, 2025, down from €9.4M at year-end 2024, with a runway into January 2026, excluding potential SEPA funds.
Outlook and guidance
Preparations for a dedicated Phase 2b study in diabetic kidney disease are underway, with protocol discussions ongoing and CRO selection in final stages; study start is contingent on securing additional funding or partnerships.
Top-line data from the Phase 2b study expected within 24 months of initiation.
Operating plan supports kidney disease strategy and IP strengthening.
Ongoing operating losses and need for further capital are anticipated for the foreseeable future.
Material uncertainty exists regarding the ability to continue as a going concern in 2026 without new funding.
What is the ideal partnership timing for Phase IIb?
What funding is needed for VY2149 preclinical?
What are key considerations for Phase IIb protocol?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Vivoryon Therapeutics earnings date
Q3 20258 Dec, 2025
Next Vivoryon Therapeutics earnings date
Q3 20258 Dec, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Vivoryon Therapeutics N.V., previously known as Probiodrug, is a Germany-based clinical-stage biopharmaceutical company. It specializes in the discovery and development of therapies for patients suffering from age-related diseases, with a primary focus on Alzheimer’s disease and cancer immune checkpoint inhibition. The company leverages its expertise in understanding post-translational modifications to develop small molecule medications that modulate the activity and stability of proteins altered in disease settings. The company is headquartered in Halle (Saale), Germany, and its shares are listed on the Euronext Amsterdam.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage